Similar articles

• Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease.

  Allen LaPointe NM, Zhou Y, Stafford JA, Hernandez AF, Kramer JM, Anstrom KJ. Allen LaPointe NM, et al. Am J Cardiol. 2009 Jun 1;103(11):1518-24. doi: 10.1016/j.amjcard.2009.01.363. Epub 2009 Apr 8. Am J Cardiol. 2009. PMID: 19463509
• Angiotensin-converting enzyme inhibitors, beta-blockers, and mortality in systolic heart failure.

  Thornton PL, Ahmed A. Thornton PL, et al. J Am Coll Cardiol. 2004 Apr 7;43(7):1333; author reply 1333-4. doi: 10.1016/j.jacc.2004.01.005. J Am Coll Cardiol. 2004. PMID: 15063454 No abstract available.
• Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease.

  Vonder Muhll I, Liu P, Webb G. Vonder Muhll I, et al. Int J Cardiol. 2004 Dec;97 Suppl 1:25-33. doi: 10.1016/j.ijcard.2004.08.006. Int J Cardiol. 2004. PMID: 15590076 Review.
• Managing patients with heart failure: the reality of clinical practice.

  Squire I. Squire I. Eur Heart J. 2005 Dec;26(24):2611-3. doi: 10.1093/eurheartj/ehi597. Epub 2005 Oct 11. Eur Heart J. 2005. PMID: 16219652 No abstract available.
• [Guidelines for the therapy of heart failure: importance of the treatment individualization].

  Ceia F. Ceia F. Rev Port Cardiol. 1999 Apr;18(4):439-45. Rev Port Cardiol. 1999. PMID: 10371853 Review. Portuguese.